Guillain — Barré Syndrome in Inflammatory Joint Diseases

作者: S.V. Selezneva , A.V. Perepada , O.V. Syniachenko , Ye.D. Yehudina , A.A. Khaniukov

DOI: 10.22141/2224-0713.5.83.2016.78471

关键词:

摘要: Background. Guillain — Barre syndrome (GBS) in joints inflammatory diseases is described several surveys, and many clinical pathogenic aspects of this peripheral neuropathy (PNP) remain obscure. Objective. To evaluate the incidence nature course GBS rheumatoid arthritis (RA), chlamydia urogenital reactive (ReA), psoriatic (PA) ankylosing spondylitis (AS), to study issues structure neuropathy, identify risk factors. Material methods. The included 416 patients with joint diseases, among them 131 RA patients, 101 ReA, 76 PA 108 AS. average age examined persons was 45, 32, 42 38 years old, respectively, disease duration 10, 4, 12 11 years, male female ratio — 1 : 5, 1 : 1, 1 : 2 10 : 1. Results. develops 3, 5 9 % RA, PA, ReA AS, or 24, 17, 26 27 % these PNP that closely related presence tendovaginitis at all severity articular syndrome, depends on digital arteritis, hypothyroidism, Sjogren’s ReA — on violations excitability myocardium heart electrical conduction, A — on exudative form cutaneous psoriasis, AS — on osteoporosis, immune disorders, processes endothelial dysfunction vascular changes physic-chemical adsorption-rheological viscoelastic relaxation properties blood participate pathogenesis GBS. Conclusion. correlated laboratory signs future such active detection pathology nervous system will be useful for timely follow-up rehabilitation, and, seropositive results by anti-cyclic citrullinated peptide antibodies are factor PNP.

参考文章(14)
Alba Velázquez Benito, Elena Bellosta Diago, Sonia Santos Lasaosa, Luis Fernando Pascual Millán, Neuropatía axonal aguda sensitivo-motora (síndrome de Guillain-Barré) tras vertebroplastia Medicina Clinica. ,vol. 143, pp. 282- 283 ,(2014) , 10.1016/J.MEDCLI.2013.11.017
Marco Turatti, Stefano Tamburin, Domenico Idone, Maria Luigia Praitano, Giampietro Zanette, Guillain-Barré syndrome after short-course efalizumab treatment. Journal of Neurology. ,vol. 257, pp. 1404- 1405 ,(2010) , 10.1007/S00415-010-5521-8
Amre Nouh, Olimpia Carbunar, Sean Ruland, Neurology of Rheumatologic Disorders Current Neurology and Neuroscience Reports. ,vol. 14, pp. 456- 456 ,(2014) , 10.1007/S11910-014-0456-6
B. Mulhearn, I. N. Bruce, Indications for IVIG in rheumatic diseases Rheumatology. ,vol. 54, pp. 383- 391 ,(2015) , 10.1093/RHEUMATOLOGY/KEU429
S. Pouwels, A. de Boer, H. G. M. Leufkens, W. E. J. Weber, C. Cooper, T. P. van Staa, F. de Vries, Risk of fracture in patients with Guillain-Barré syndrome Osteoporosis International. ,vol. 25, pp. 1845- 1851 ,(2014) , 10.1007/S00198-014-2705-6
Haruki Koike, Hirohisa Watanabe, Gen Sobue, The spectrum of immune-mediated autonomic neuropathies: Insights from the clinicopathological features Journal of Neurology, Neurosurgery, and Psychiatry. ,vol. 84, pp. 98- 106 ,(2013) , 10.1136/JNNP-2012-302833
Sandro Sonnino, Elena Chiricozzi, Maria Grazia Ciampa, Laura Mauri, Alessandro Prinetti, Gino Toffano, Massimo Aureli, Serum Antibodies to Glycans in Peripheral Neuropathies Molecular Neurobiology. ,vol. 54, pp. 1564- 1567 ,(2017) , 10.1007/S12035-016-9775-8
Yuanyuan Che, Jinpeng Qiu, Tao Jin, Fei Yin, Man Li, Yanfang Jiang, Circulating memory T follicular helper subsets, Tfh2 and Tfh17, participate in the pathogenesis of Guillain-Barré syndrome Scientific Reports. ,vol. 6, pp. 20963- 20963 ,(2016) , 10.1038/SREP20963
Nikki van Leeuwen, Hester F. Lingsma, Ann M. Vanrolleghem, Miriam C. J. M. Sturkenboom, Pieter A. van Doorn, Ewout W. Steyerberg, Bart C. Jacobs, Hospital Admissions, Transfers and Costs of Guillain-Barré Syndrome PLOS ONE. ,vol. 11, pp. e0143837- ,(2016) , 10.1371/JOURNAL.PONE.0143837